AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06371430 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dental Implant insertion and tooth extraction
Description: The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment.
Study NCT06371430 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Dental Implant insertion and tooth extraction
Description: The osteotomies were carried out at a speed of 800 rpm, using sequential burs of similar diameter for both the maxilar and the mandibular side. The drilling protocols followed the recommendations provided by the manufacturer, the Galaxy-Ziacom implant system, for standard drilling.~The insertion of the implants was initiated using a motor handpiece at a speed of 20-50 rpm, without irrigation. The installation process was completed using a manual surgical torque wrench indicator. The maximum torque value (Ncm) reached at the end of implant insertion was recorded as the insertion torque (IT). A total of 264 implants were inserted in 33 patients, 160 implants were post-extraction and 104 implants were inserted after at least one-month post-extraction. The sutures were typically removed 1 week after the surgery, during the postoperative follow-up appointment.
Study NCT05649345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TR64
Description: TR64 tablets will be given daily for 28 days in 28-day cycles until there appears evidence of progressive disease, intolerable toxicity, or the subject discontinues from the study treatment for other reasons.
Study NCT04707196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT04707196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nonsteroidal Aromatase Inhibitor (NSAI)
Description: Letrozole or anastrozole administered orally (physician choice)
Study NCT04707196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Administered intramuscularly
Study NCT04993508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSA test
Description: testing for blood levels of PSA
Study NCT04993508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: PSA test
Description: testing for blood levels of PSA
Study NCT04993508 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSA test
Description: testing for blood levels of PSA
Study NCT04993508 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multiparametric prostate Magnetic Resonance Imaging (mpMRI)
Description: mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD > 0.15 will considered suspicious for csPCa.
Study NCT05005338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB122 (DNL151)
Description: Oral doses
Study NCT05005338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BIIB122 ([14C] DNL151)
Description: Intravenous doses
Study NCT05758922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ-3102 (Dose 1)
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT05758922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT05758922 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZ-3102 (Dose 2)
Description: Pharmaceutical form: capsule~Route of administration: oral
Study NCT05016544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inetetamab
Description: All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
Study NCT05016544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pytotinib
Description: Starting pytotinib Dose of 240mg:~Cohort 1: pyrotinib 240mg p.o. d1 to d21, q3w; Cohort 2: pyrotinib 320mg p.o. d1 to d21, q3w; Cohort 3: pyrotinib 400mg p.o. d1 to d21, q3w.
Study NCT06264544 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc, selenium, and L-tyrosine in SEPP1
Description: zinc, selenium, and L-tyrosine in SEPP1 polymorphism
Study NCT06264544 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator in SEPP1 polymorphism group
Study NCT04404478 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: B-SWELL: Midlife Black Women's Stress Reduction Wellness Program
Description: Stress reduction and culturally tailored information on healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on per support, goal setting, stress reduction, and culturally relevant information.
Study NCT04404478 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WE: Wellness program for Midlife Black Women
Description: Culturally tailored information will be provided about healthy lifestyle behaviors will be used to increase healthy lifestyle behaviors according to the AHA's Life's Simple 7. Focus of intervention on peer support and culturally relevant content.
Study NCT04479722 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure procedure
Description: Implant LAAC system in LAA through percutaneous intervention
Study NCT04479722 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Left atrial appendage closure procedure
Description: Implant LAAC system in LAA through percutaneous intervention
Study NCT04860414 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
Study NCT04860414 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Fasting blood glucose, dosage of acylated and non-acylated ghrelin, leptin, insulin and serotonin.
Study NCT04993508 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: multiparametric prostate Magnetic Resonance Imaging (mpMRI)
Description: mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD > 0.15 will considered suspicious for csPCa.
Study NCT04993508 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: multiparametric prostate Magnetic Resonance Imaging (mpMRI)
Description: mpMRI acquisition and reporting will be performed according to the current version of the Prostate Imaging-Reporting and Data System (PI-RADS). MpMRI will be performed at the different study centers on a 3 Tesla MR scanner using multi-phased array surface coil. MpMRI includes T1-weighted and T2-weighted imaging (T1WI, T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced imaging (DCE-MRI). Hyoscine butyl bromide will be administered to optimize image quality. Prostate imaging quality will be assessed by the prostate imaging quality score (PI-QUAL). In case of contraindications to MRI contrast agents, DCE will be omitted. In case of contraindications to hyoscine butyl bromide, it will be omitted. Lesions with a PI-RADS score of ≥ 4 and 3 with PSAD > 0.15 will considered suspicious for csPCa.
Study NCT04993508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: targeted MRI/US fusion-guided biopsy
Description: Targeted MRI/US fusion-guided biopsy (TB) are performed using transrectal ultrasound (max. 6 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
Study NCT04993508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: combined prostate biopsy (systematic biopsy plus targeted MRI/US fusion-guided biopsy)
Description: The combined biopsy comprises systematic biopsy (SB) and targeted MRI/US fusion-guided biopsy (TB). They are performed using transrectal ultrasound (number of cores: SB 12 cores, TB max. 6 cores from 3 targets). MRI/US fusion-guided biopsies can be performed transrectally or transperineally. Ultrasound-guided biopsies will be performed with a 3-D probe and with local or general anesthesia. Coverage with antibiotics has to be provided as per local standard of care for all biopsies.
Study NCT04993508 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI inbore biopsy
Description: MRI inbore biopsies will be offered after negative initial MRI/US fusion-guided biopsy or diagnosis of only clinically insignificant PCa in initial biopsy in arms A or B. Before performing MRI inbore biopsy the PI-RADS scoring will be re-confirmed. The number of cores will be 2 per target. In case of inaccurate needle position additional cores are allowed to ensure correct targeting. Needle position will be verified in 2 planes. Coverage with antibiotics has to be provided as per local standard of care.
Study NCT04993508 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MRI inbore biopsy
Description: MRI inbore biopsies will be offered after negative initial MRI/US fusion-guided biopsy or diagnosis of only clinically insignificant PCa in initial biopsy in arms A or B. Before performing MRI inbore biopsy the PI-RADS scoring will be re-confirmed. The number of cores will be 2 per target. In case of inaccurate needle position additional cores are allowed to ensure correct targeting. Needle position will be verified in 2 planes. Coverage with antibiotics has to be provided as per local standard of care.
Study NCT04867707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanamivir
Description: 5 days of treatment with 10mg zanamivir inhaler BID
Study NCT06487221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avutometinib
Description: 3.2mg orally
Study NCT06487221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Defactinib
Description: 200 mg orally
Study NCT05461521 — intervention group
Intervention type: OTHER
Intervention: Family members of patients admitted to the ICU
Description: At inclusion:~* Collection of demographic data, Anxiety-Depression Scale (HADS), Insomnia Severity Index (ISI), Resilience Insomnia Severity Index (ISI), Resilience Scale (CD RISC 10), Peritraumatic Dissociation Peritraumatic Dissociation Experience Scale (PDEQ) and MEDEC questionnaire.~* Venous blood sampling at 350 relatives~* Upon discharge of the patient (alive or deceased): Resuscitation questionnaire, HADS, ISI and PDEQ.~  3 months after discharge: Demographic questionnaire, Post Traumatic Stress Disorder questionnaire (PCL-5), THS Past Trauma Experience Questionnaire, HADS experiences, HADS, ISI, CD RISC 10, MEDEC and Who- assist questionnaire (Question 2) on the use of psychoactive substances.~  6 months after patient discharge: PCL-5, HADS, ISI, CD RISC 10, MEDEC, Who-assist (Question 2) and Prolonged Grief disorder (PG-13) questionnaire on bereavement if patient died in the ICU.
Study NCT05461521 — intervention group
Intervention type: OTHER
Intervention: Health care professionals
Description: All professionals in all categories and in all participating departments will be asked to complete questionnaires to assess the level of conflict, work stress and burn out in the units : Masclach Burnout Inventory (MBI), Job Content Questionnaire (JCQ), Ethical Decision-Making Climate Questionnaire (EDMCQ), Professional Quality Of Life scale (ProQOL), Connor-Davidson Resilience scale (CD-RISC 10), Cultural Awareness Scale (CAS).
Study NCT05461521 — intervention group
Intervention type: OTHER
Intervention: Patients
Description: Inclusion (at D3 after admission to the ICU): collection of demographic data Discharge from the ICU: characteristics of the stay and outcome (alive/deceased)
Study NCT06162715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Tirzepatide will be initiated 12 months after patients undergo Roux-en-Y Gastric Bypass. Patients will be started on the lowest dose of 2.5 mg and the dose increased every 6 weeks following an adaptive maximum dose titration protocol. Patients will then complete a final 4 weeks of the study drug.
Study NCT06162715 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of Care post-gastric bypass
Description: Patients randomized to the control arm will receive the standard of care for weight maintenance after gastric bypass including dietary guidance provided by the Vanderbilt Surgical Weight Loss handbook. This includes recommendations for 64 oz of fluids per day, ≥60 grams of protein/day, and daily bariatric multivitamins. Patients will continue to have access to dedicated bariatric dietitians, advanced practice providers, and surgeons on an ad hoc basis per patients' request.
Study NCT04860414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Assessment
Description: QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
Study NCT04764331 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Revian Red All LED cap
Description: Cap that uses two wavelengths of light, 620 nm and 660 nm will be used once a day for 10 minutes.for treatment
Study NCT06231693 — intervention group
Intervention type: DRUG
Intervention: Trastuzumab deruxtecan
Description: Patients with RE\<10% and HER2-Low breast cancer that have received Trastuzumab-deruxtecan in the metastatic setting
Study NCT05929729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric derisomaltose
Description: Refer to arm/group descriptions
Study NCT05929729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NovaFerrum
Description: Refer to arm/group descriptions
Study NCT06564506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Disposable acupuncture needles (0.30 × 75 mm)
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
Study NCT06564506 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo needles (0.30 × 25 mm)
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Sham electroacupuncture will use blunt-tipped placebo needles without current output, which retract into their handles to simulate skin insertion.
Study NCT06564506 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SDZ-V electroacupuncture devices
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
Study NCT06564506 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SDZ-V electroacupuncture devices
Description: Disposable acupuncture needles (0.30 × 75 mm), placebo needles (0.30 × 25 mm) and SDZ-V electroacupuncture devices (Hwato, Suzhou Medical Supplies Factory Co Ltd, China) will be used. Electrodes attached to the needle handles will deliver stimulation for 30 minutes (2 Hz/15 Hz frequency, 1 mA intensity) to cause mild skin movement without pain.
Study NCT05248230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4D-710
Description: 4D-710 is an adeno-associated virus (AAV) gene therapy comprised of an AAV capsid variant (4D-A101) carrying a transgene cassette encoding human cystic fibrosis transmembrane conductance regulator with a deletion in the regulatory domain (CFTRΔR).
Study NCT05987904 — intervention group
Intervention type: DEVICE
Intervention: LynxPatch
Description: Measurements with the LynxPatch device are conducted.
Study NCT05821959 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: AAVAnc80-hOTOF via Akouos Delivery Device
Description: AAVAnc80-hOTOF is a sterile suspension intended to be administered via a one-time unilateral intracochlear administration using the Akouos Delivery Device.
Study NCT06200311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation
Description: Pulmonary vein isolation using pulsed field ablation (PFA), cryoballoon or radiofrequency ablation (RFA)
Study NCT06200311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological rhythm management
Description: 1st line: rate control, 2nd line: pharmacological rhythm management. 3rd line: AF ablation
Study NCT04860414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Assessment
Description: QPC Cognitive complaint questionnaire, CDR functional autonomy scales and IADL 4 items, MMSE cognitive scores, Dubois 5-word test, clock test, BREF, Isaacs test, BARD naming battery and MADRS depression scale
Study NCT04860414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subjective taste tests
Description: Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
Study NCT04860414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subjective taste tests
Description: Scales of taste perceptive intensity, taste pleasure, hunger sensation (visual analogue scales from 0 to 10 cm) and food preferences on the one hand, and on the other hand, subjective tests of taste threshold determination by triangular tests of increasing sugar solution concentrations.
Study NCT04860414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Objective taste tests
Description: Recording of gustatory evoked potentials
Study NCT04860414 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Objective taste tests
Description: Recording of gustatory evoked potentials
Study NCT05138159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafenib
Description: Donafenib: 200mg po bid.
Study NCT05138159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1 capsule: According to the body surface area \<1.25m2 40mg/d, 1.25 \~ 1.5 m2 50 mg/d, > 1.5m2 60mg/d po bid, taking 14 days, stopping for 7 days, 21 days for 1 cycle.
Study NCT05299021 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Double-point SAPB
Description: A high-frequency linear probe (6-13 MHz) of the ultrasound machine was used to identify the fifth rib in the midaxillary line. The anatomic landmarks of the block were identified: latissimus dorsi, serratus anterior, and the intercostal muscles in the fourth and fifth intercostal levels. After sterilization and draping, an 20-gauge needle was introduced craniocaudally using an in-plane technique. The needle tip was advanced, targeting the plane between the serratus anterior muscle and the fifth rib. Needle position was confirmed by injection of 1-to-2 mL of saline after negative aspiration. And use the same method targeting the plane between the serratus anterior muscle and the third rib.Under real-time visualization, total 30 mL of 0.375% ropivacaine and 0.5 μ g/kg dexmedetomidine mixture will be injected into the two points with 15 ml separately.
Study NCT04774419 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiation therapy (IMRT)
Description: To the pelvic nodes and vaginal cuff (total dose of 45-50.4Gy at 1.8 Gy per fraction) for 5-6 weeks.
Study NCT04774419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: IV Dostarlimab every 3 weeks for 4 cycles followed by 1 dose of 1000mg (C5). Patients will receive a maximum of 5 cycles of Dostarlimab.